William Young to retire from Biogen’s board of directors after 17 years
US biotech firm Biogen Idec (Nasdaq: BIIB) has announced today that chairman of the board William Young, known as Bill, will retire from the company’s Board of Directors, effective at the company’s 2014 annual meeting of stockholders.
Mr Young has been a member of Biogen Idec’s Board of Directors since 1997 and has served as Chairman of the Board since 2010.
George Scangos, chief executive officer of Biogen Idec, said: “Bill’s leadership and dedication to Biogen Idec cannot be overstated. The integrity and determination that he brought to this organization serve as a benchmark for future leaders to follow. On behalf of the Board of Directors and Biogen Idec, I would like to thank Bill for his long-standing service and wish him the best for the future.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze